"He promised more jobs and more security," says Jim茅nez, who recounts being robbed and receiving extortion calls demanding cash in recent months. "It's been completely the opposite."
Pe帽a Nieto arrived in office one year ago on Dec. 1, 2012, promising to calm the country and produce long-stalled structural reforms, which he said would allow Mexico to achieve 6% annual growth.
"This is Mexico's moment," he said in his inaugural address ��a line often repeated by boosters and analysts alike, summing up the sense of optimism for the Pe帽a Nieto as he attempted to turn the page on years of insecurity and subpar economic growth.
Hot Telecom Companies For 2016: SandRidge Mississippian Trust I (SDT)
SandRidge Mississippian Trust I (The Trust) is a statutory trust. The Trust was created to acquire and hold the Royalty Interests for the benefit of Trust unitholders. SandRidge conveyed to the Trust the Royalty Interests in specified oil and natural gas properties in the Mississippian formation in Alfalfa, Garfield, Grant, Major and Woods counties in Oklahoma (the Underlying Properties). These Royalty Interests were derived from SandRidge�� interests in a 36 wells and the equivalent of 123 horizontal development wells to be drilled in the Mississippian formation (Trust Development Wells) within an area of mutual interest (AMI), consisting of approximately 49,600 gross acres (42,000 net acres) in the counties where the Underlying Properties are located.
Effective January 1, 2011, the Royalty Interests entitle the Trust to receive 90% of the proceeds from the sale of oil and natural gas production attributable to its net revenue interest in the Initial Wells and 50% of the proceeds from the sale of oil and natural gas production attributable to SandRidge�� net revenue interest in the Trust Development Wells. As of December 31, 2011, the Trust�� properties consisted of Royalty Interests in the Initial Wells, 48 wells (equivalent to approximately 53 Trust Development Wells under the development agreement) and the equivalent of approximately 70 Trust Development Wells to be drilled in the Mississippian formation.
Advisors' Opinion:- [By Matt DiLallo]
SandRidge Mississippian Trust I (NYSE: SDT ) and Trust II (NYSE: SDR )
These trusts were created by SandRidge Energy (NYSE: SD ) , with the first Mississippian Trust formed in 2010 and the second formed one year later. Both trusts own royalty interests in oil and gas properties targeting the Mississippian formation and have future upside as SandRidge drills wells as part of the areas of mutual interest. - [By Dan Caplinger]
SandRidge has made a huge bet on the Mississippian Lime shale play, especially after selling off its Permian Basin assets late last year. Unfortunately, that bet hasn't paid off well for shareholders, as the company saw its spun-off royalty trusts SandRidge Mississippian Trust I (NYSE: SDT ) and SandRidge Mississippian Trust II (NYSE: SDR ) fail to meet their projections for distribution amounts during the first quarter. The main problem has been that wells in the Mississippian Lime have produced more natural gas than expected, and even with a slight rebound in gas prices, it still doesn't produce adequate margins compared to oil and natural-gas liquids.
- [By Adam Galas]
As the chart illustrates, SandRidge's other royalty trust,�SandRidge Mississippian Trust I (NYSE: SDT ) , which has already had its final wells drilled, has been experiencing a severe decline in distributions, a result of its massive quarterly production declines of 26%, 21%, and 22% immediately after the last well was drilled.�
Top Diversified Bank Companies For 2015: Fluor Corporation(FLR)
Fluor Corporation, through its subsidiaries, provides engineering, procurement, construction, maintenance, and project management services worldwide. Its Oil & Gas segment offers design, engineering, procurement, construction, and project management services to upstream oil and gas production, downstream refining, chemicals, and petrochemicals industries. This segment also provides consulting services comprising feasibility studies, process assessment, and project finance structuring and studies. The company?s Industrial & Infrastructure segment offers design, engineering, procurement, and construction services to the transportation, wind power, mining and metals, life sciences, manufacturing, commercial and institutional, telecommunications, microelectronics, and healthcare sectors. Its Government segment provides engineering, construction, logistics support, contingency response, management, and operations services to the United States government focusing on the Departme nt of Energy, the Department of Homeland Security, and the Department of Defense. The company?s Global Services segment offers operations and maintenance, small capital project engineering and execution, site equipment and tool services, industrial fleet services, plant turnaround services, temporary staffing services, and supply chain solutions. Its Power segment provides engineering, procurement, construction, program management, start-up and commissioning, and operations and maintenance services to the gas fueled, solid fueled, plant betterment, renewables, nuclear, and power services markets. The company also offers unionized management and construction services in the United States and Canada. Fluor Corporation was founded in 1912 and is headquartered in Irving, Texas.
Advisors' Opinion:- [By Rich Duprey]
South America has become an unsettled region to mine in. Newmont Mining (NYSE: NEM ) had its Peruvian Conga project brought to a short stop over environmental concerns, while Vale (NYSE: VALE ) recently abandoned an Argentinean project because of the country's policies.�Costs for Pascua-Lama have ballooned over the past decade and now stand at about $8.5 billion, putting it at risk of becoming an albatross around the miner's neck even before the court decision. Barrick even resorted to bringing in engineering specialist Fluor (NYSE: FLR ) to expand the scope of its project management before the court order.
- [By Louis Navellier]
Fluor Corporation (FLR) is one of the world�� leading heavy construction and engineering firms. I don’t want to imply that this is a bad company because it is actually a very good one. However, Fluor has divisions including Oil & Gas, Industrial Infrastructure, Government, Global Services and Power. Virtually all of them are seeing limited spending as a result of the global slowdown and reduced government spending around the world. The stock is up more than 23% this year, but earnings are actually down on flat revenues. Analysts have been lowering their estimates for the rest of this year as well as 2014, and the stock is currently rated as a by Portfolio Grader. When the economy recovers, I expect will see this company’s fundamentals improve substantially … but until that happens investors should avoid the stock.
- [By Ben Levisohn]
Deutsche Bank’s Vishal Shah and team consider the impact on Chicago Bridge & Iron, as well as Fluor (FLR), who had a competing bid:
While the award of Cameron LNG is clearly a positive for [Chicago Bridge & Iron], we believe this project could provide upside of $1.6B to our current new award estimate of $13.6B for 2014. Additionally, this project win further supports�[Chicago Bridge & Iron] as a leader in [liquefied natural gas] projects. The company is currently in the running for Golden Pass LNG ($10B), Anadarko Mozambique LNG ($15B, competing against FLR) and Russia Far East LNG ($15B), all of which will likely be awarded in 2015. As for [Fluor], our probability-weighted new award estimate for Cameron was $1.4B, which suggests that 2014 new awards could be $24.6B, vs. our current estimate of $26.0B.
Top Diversified Bank Companies For 2015: Commonwealth Bank of Australia (CBA)
Commonwealth Bank of Australia (the Bank) is engaged in the provision of a range of banking and financial products and services to retail, small business, corporate and institutional clients. The Bank is a provider of integrated financial services, including retail, business and institutional banking, superannuation, life insurance, general insurance, funds management, broking services and finance company activities. Its operating segments include Retail Banking Services, Business and Private Banking, Institutional Banking and Markets, Wealth Management, New Zealand, Bankwest and Other. Its retail banking services include home loans, consumer finance, retail deposits and distribution. Its business and private banking include corporate financial services, regional and agribusiness banking, local business banking, private bank and equities and margin lending. The Bank and its subsidiaries ceased to be a substantial holder in Ten Network Holdings Limited, as of September 12, 2012. Advisors' Opinion:- [By Michael Ugulini]
Investors can take away that Craft Brew Alliance (CBA) is experiencing growth in all brands as noted by the company's President of Commercial Operations, Mr. Andy Thomas in an August Earning's Call, "For the first time in CBA's history, CBA's quarterly growth was propelled by growth in all brand families and across all CBA sales divisions. Our overall plus 12% STR growth came from a healthy blend of plus 23% growth for Kona, plus 14% growth for Redhook, and plus 1% growth for Widmer Brothers; all accompanied by the continued expansion of Omission in our international markets."
Top Diversified Bank Companies For 2015: Apricus Biosciences Inc(APRI)
Apricus Biosciences, Inc. engages in the design and development of pharmaceutical products and product candidates based on its patented NexACT drug delivery technology. The NexACT drug delivery technology is designed to enhance the delivery of an active drug to improve therapeutic outcomes and reduce systemic side effects that accompany existing oral and injectable medications. The company?s pipeline includes Vitaros, approved in Canada for the treatment of erectile dysfunction; and Totect approved in the U.S. for the treatment of anthracycline extravasation, as well as compounds in development from pre-clinical through pre-registration, focused on sexual dysfunction, oncology, dermatology, autoimmune, pain, anti-infectives, diabetes, and consumer healthcare. The company was founded in 1987 and is headquartered in San Diego, California.
Advisors' Opinion:- [By John Udovich]
On Friday, small cap pharma stock Apricus Biosciences Inc (NASDAQ: APRI) jumped just over 10% and not only�did the stock hold onto those gains, it made�another 10% jumps on Monday���meaning its time to take a closer look at the stock along with the performance of other potential benchmarks in the sexual health or reproductive health spaces like The Female Health Company (NASDAQ: FHCO) and Repros Therapeutics Inc (NASDAQ: RPRX).
- [By Eric Volkman]
Apricus Biosciences (NASDAQ: APRI ) is hoping to widen its capital base significantly. The company is floating a mix of common stock and warrants that it hopes will raise net proceeds of nearly $16 million. Six million shares will be sold in an underwritten public offering at $2.85 apiece, and 3 million warrants will be issued separately at an exercise price of $3.40 per share.�
- [By Jon C. Ogg]
Apricus Biosciences Inc. (NASDAQ: APRI) was initiated with a Hold rating and a $2 price target at Cantor Fitzgerald. Be advised that $2 is almost 10% under the prior close of $2.18, against a 52-week range of $1.89 to $3.49.
Top Diversified Bank Companies For 2015: ImmunoCellular Therapeutics Ltd (IMUC)
ImmunoCellular Therapeutics, Ltd., incorporated on March 20, 1987, is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�� own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�� products include ICT-107, ICT-140, ICT-120, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�� immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).
The Company in addition to ICT-107, is also developing other therapeutic DC vaccines: ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-107 is a DC vaccine that targets six different tumor-associated antigens that are found on patients��tumor cells; four of the six antigens are expressed on CSCs. The therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed GBM. ICT-140 is a DC vaccine that targets seven different ovarian cancer antigens. ICT-121 is a DC vaccine that targets CD133 antigens; it has the potential to be a universal cancer vaccine because CD133 is widely expressed on CSCs from a majority of cancers. Data from this small study demonstrated that ICT-109 had a statistically ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets. The DIAAD (differential immunization for an! tigen and antibody discovery) platform it acquired from Molecular Discoveries utilizes immunological tolerization to accelerate the discovery of the molecular differences between diseased cells and their normal counterparts. The monoclonal antibodies produced by DIAAD provide the basis for the discovery and development of its potential diagnostic and therapeutic products.
The Company competes with Dendreon, Oncothyreon, Galena, Bavarian Nordic and Immunovaccine, Northwest Biotherapeutics, Prima Biomed, DCPrime, Roche/Genentech, Seattle Genetics, Bristol-Myers Squibb and Immunogen.
Advisors' Opinion:- [By Wallace Witkowski]
Shares of ImmunoCellular (IMUC) �jumped after the drug developer said data on a mid-stage brain cancer drug study were looking encouraging.
- [By Monica Gerson]
ImmunoCellular Therapeutics (NYSE: IMUC) dropped 11.05% to $1.3699. ImmunoCellular's trailing-twelve-month ROE is -59.80%.
Posted-In: market losersNews Movers & Shakers Intraday Update Markets
- [By Smith On Stocks]
Using my assumptions, the common of Agenus might be worth about $7.00 per share in early 2014 based on the royalties from the Glaxo vaccines and the net operating loss carry forward even if every other asset in the company were valued at zero. However, there may be substantial value in Agenus' internal vaccine programs in recurrent and newly diagnosed glioblastoma and the genital herpes vaccine. Based on a comparison to peer companies like Northwest Biotherapeutics (NWBO) and ImmunoCellular Therapeutics (IMUC), I believe that the internal programs at Agenus currently may be worth $150 million or $4.45 per share. Adding this to the value of the MAGE A-3 vaccine could produce a stock price of $11.00 in early 2014.
Top Diversified Bank Companies For 2015: GenMark Diagnostics Inc.(GNMK)
GenMark Diagnostics, Inc. operates as a molecular diagnostics company primarily in the United States. It focuses on the development and commercialization of multiplexed molecular diagnostic testing systems for the detection and measurement of DNA and RNA targets used in the treatment of patients. The company?s products comprise eSensor XT-8 system, an automated molecular diagnostic system, which enable reference laboratories and hospitals to perform molecular diagnostic tests; and eSensor XT-8 Cartridge that utilizes a microfluidic system to accelerate target binding and enhance time to result. It also offers IVD tests, including eSensor cystic fibrosis genotyping test, eSensor thrombophilia risk test, and eSensor warfarin sensitivity test. The company?s other multiplexed molecular diagnostic tests pipeline under development comprise eSensor 2C19 test for the multiplexed detection and genotyping of various alleles of the cytochrome P450 (CYP450) 2C19 gene locus; eSensor respiratory viral panel, a nucleic acid multiplex test for the simultaneous detection and identification of multiple respiratory virus nucleic acids and mutations that confer resistance of Influenza A to the anti-viral drug Oseltamivir (Tamiflu); and eSensor KRAS/BRAF test for the multiplexed detection and genotyping of 12 mutations in codons 12 and 13 of KRAS and the V600E mutation in BRAF. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Advisors' Opinion:- [By Sean Williams]
What: Shares of GenMark Diagnostics (NASDAQ: GNMK ) , a molecular diagnostics company, slumped as much as 10% after updating its full-year revenue guidance after the bell last night.
- [By Roberto Pedone]
GenMark Diagnostics (GNMK) is a molecular diagnostics company, engages in the development, manufacturing, marketing, sale, and support of instruments and molecular tests based on its proprietary eSensor detection technology in the U.S. This stock closed up 1.7% to $9.89 in Tuesday's trading session.
Tuesday's Range: $9.24-$9.95
52-Week Range: $6.38-$16.00
Thursday's Volume: 562,000
Three-Month Average Volume: 385,008From a technical perspective, GNMK bounced modestly higher here with above-average volume. This stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $8.75 on the downside and $10.71 on the upside. This bounce is starting to push GNMK within range of triggering a near-term breakout trade above the upper-end of its sideways trading chart pattern. That breakout will hit if GNMK manages to clear some near-term overhead resistance levels at $10.04 to $10.50 and then once it takes out more resistance at $10.71 with high volume.
Traders should now look for long-biased trades in GNMK as long as it's trending above Tuesday's low of $9.24 or around $9 and then once it sustains a move or close above those breakout levels with volume that hits near or above 385,008 shares. If that breakout triggers soon, then GNMK will set up to re-test or possibly take out its next major overhead resistance levels at $12 to $13.50.
No comments:
Post a Comment